Related Experiment Video
Updated: Apr 19, 2026
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
Published on: January 27, 2023
Meriva®+Glucosamine versus Condroitin+Glucosamine in patients with knee osteoarthritis: an observational study
1Department of Biomedical Sciences, Irvine 3 Labs, Circulation Sciences, Chieti-Pescara University, Italy. cardres@abol.it.
Objective:
Osteoarthritis (OA) is a major cause of physical disability and impaired quality of life. Non-steroidal anti-inflammatory drugs are the most used treatment for OA, but they are frequently associated to adverse events. Alternative therapies are under investigation for the treatment of OA. Meriva® is a lecithin delivery form of curcumin, a powerful promoter of anti-oxidant response studied in a number of conditions related to chronic inflammation and pain.
Patients And Methods:
This 4-month observational study, conducted in a 'real-life' scenario, compares the association of Meriva and glucosamine (n=63) with chondroitin sulphate+glucosamine (n=61) in 124 patients with grade 1-2 OA of the knee.
Results:
Patients treated with Meriva+glucosamine had significantly higher Karnofsky Index and WOMAC score (both in the physical and emotional domains), compared to those in the chondroitin+glucosamine group. Noteworthy, the walking distance at the treadmill test after 1 month was also significantly higher in the meriva+glucosamine group; this advantage was sustained until the end of the study. Although the need for concomitant drugs and medical attention decreased in both groups, this reduction was more evident for patients treated with Meriva+glucosamine.
Conclusions:
Taken together, the results of this study shows that the 4-month administration of the association of Meriva and glucosamine can result in a faster onset of action and improved outcomes than the administration of an association of chondroitin sulphate and glucosamine in patients with OA.
Insights
Meriva and glucosamine combination therapy offers faster relief and better outcomes for osteoarthritis (OA) patients compared to chondroitin and glucosamine. This study highlights Meriva
Area of Science:
- Rheumatology and Orthopedics
- Nutraceuticals and Dietary Supplements
- Pain Management and Inflammation
Background:
- Osteoarthritis (OA) significantly impacts quality of life, with NSAIDs being common but having adverse effects.
- Curcumin, delivered via Meriva (a lecithin-based formulation), shows promise for chronic inflammation and pain.
- Investigating alternative OA therapies is crucial due to limitations of current treatments.
Purpose of the Study:
- To compare the efficacy of Meriva plus glucosamine versus chondroitin sulphate plus glucosamine in knee OA patients.
- To evaluate treatment outcomes in a real-world clinical setting over a 4-month period.
Main Methods:
- A 4-month observational study involving 124 patients with grade 1-2 knee OA.
- Patients were divided into two groups: Meriva + glucosamine (n=63) and chondroitin sulphate + glucosamine (n=61).
- Outcomes assessed included Karnofsky Index, WOMAC scores, walking distance, and need for concomitant medications.
Main Results:
- The Meriva + glucosamine group showed significantly higher Karnofsky Index and WOMAC scores (physical and emotional domains).
- Improved walking distance was observed in the Meriva + glucosamine group after 1 month, sustained throughout the study.
- A greater reduction in the need for concomitant drugs and medical attention was noted in the Meriva + glucosamine group.
Conclusions:
- Combination therapy with Meriva and glucosamine demonstrated a faster onset of action and superior outcomes compared to chondroitin sulphate and glucosamine.
- Meriva + glucosamine offers a promising alternative for managing knee osteoarthritis symptoms.
- The findings support the use of Meriva-based formulations for OA management in real-life settings.
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
14:49Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration
Published on: September 29, 2018
